Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKinsey
Fuji
Citi
Daiichi Sankyo
Fish and Richardson
Baxter
Dow
Argus Health
Moodys

Generated: December 12, 2017

DrugPatentWatch Database Preview

ARNUITY ELLIPTA Drug Profile

« Back to Dashboard

When do Arnuity Ellipta patents expire, and what generic alternatives are available?

Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are eight patents protecting this drug.

This drug has two hundred and sixty-two patent family members in forty-one countries and twelve supplementary protection certificates in ten countries.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Drug patent expirations by year for ARNUITY ELLIPTA

Pharmacology for ARNUITY ELLIPTA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARNUITY ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-001Aug 20, 2014► Subscribe► Subscribe
GlaxosmithklineARNUITY ELLIPTAfluticasone furoatePOWDER;INHALATION205625-002Aug 20, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ARNUITY ELLIPTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,858,593 Anti-inflammatory androstane derivative compositions► Subscribe
7,541,350Formulation containing anti-inflammatory androstane derivative► Subscribe
7,144,845Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
6,537,983 Anti-inflammatory androstane derivatives► Subscribe
6,858,596 Formulation containing anti-inflammatory androstane derivative► Subscribe
7,498,32117.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents► Subscribe
6,878,698 Anti-inflammatory androstane derivatives► Subscribe
6,787,532 Formulation containing anti-inflammatory androstane derivatives► Subscribe
6,777,399 Anti-inflammatory androstane derivative compositions► Subscribe
7,125,985Compounds useful in the manufacture of an anti-inflammatory androstane derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ARNUITY ELLIPTA

Country Document Number Estimated Expiration
Japan4838494► Subscribe
Germany60131750► Subscribe
European Patent Office2348032► Subscribe
Norway20080474► Subscribe
South Africa200606421► Subscribe
MexicoPA03001096► Subscribe
United Kingdom0623405► Subscribe
Japan4508651► Subscribe
Argentina063555► Subscribe
United Kingdom0317374► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ARNUITY ELLIPTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1305329/01Switzerland► SubscribePRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
2008 00022Denmark► Subscribe
269Luxembourg► SubscribePRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
0343Netherlands► Subscribe300343, 20210803, EXPIRES: 20230110
12/2008Austria► SubscribePRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
429Luxembourg► Subscribe91429, EXPIRES: 20230111
C011/2008Ireland► SubscribeSPC011/2008: 20081105, EXPIRES: 20230110
6Finland► Subscribe
C/GB08/026United Kingdom► SubscribePRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
2008000029Germany► SubscribePRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Dow
Boehringer Ingelheim
Farmers Insurance
Fuji
Medtronic
Chinese Patent Office
McKinsey
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot